The World Health Organization (WHO) released its updated Bacterial Priority Pathogens List (BPPL) 2024, featuring 15 families of antibiotic-resistant bacteria grouped into critical, high and medium categories for prioritization. The list provides guidance on the development of new and necessary treatments to stop the spread of antimicrobial resistance (AMR).

WHO releases consolidated guidelines on HIV-associated TB providing a single comprehensive source for the latest evidence-informed TB/HIV recommendations.

SMART4TB wants to hear from you about the best person-centered language to describe TB treatment that takes severity and risk factors into account when coming up with a treatment plan. You are invited to complete a brief, five-minute questionnaire which can be accessed here.

A new meta-analysis of 17 studies reveals that tuberculosis (TB) and COVID-19 co-infection are becoming increasingly prevalent around the world, with death rates gradually declining but remaining higher than COVID-19 infection alone. The study was published yesterday in PLOS Neglected Tropical Diseases. 

The new 2024 update of An Activist’s Guide to Rifapentine TB Preventive Treatment: 3HP and 1HP lays out what TB community advocates need to know about rifapentine-based TB preventive treatment.

11 May 2024 -- Six in every 10 tuberculosis-affected households in India experience “catastrophic” costs, a study has suggested, indicating that the central TB control programme’s milestone to eliminate the infection’s economic distress to households by 2020 remains unachieved.

Key takeaways:

May 10, 2024 — How an individual’s immune system responds to the bacteria that causes tuberculosis (TB)—and therefore whether they develop the disease—may differ across age and sex, according to a new study co-led by Harvard T.H. Chan School of Public Health’s Sarah Fortune.

Imagine a world where TB doesn’t steal millions of lives each year. That dream might be inching closer, thanks to a groundbreaking vaccine trial kicking off in South Africa.

A new study suggests that countries should prioritize treatment for exposed individuals with evidence of TB infection, regardless of age — except in high-burden settings, where all exposed individuals should be considered for treatment.